leisure time -WSS

leisure time

author：explore 2025-09-30 00:46:36 - browse：9926

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Hubble vs. James Webb telescope images: See the difference

focus

hotspot

WSS

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

A letter from the executive editor: The 2023 STATUS List

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

Maui's cultural, historic landmarks damaged in the devastating wildfires

What affirmative action's end means to a medical student

American woman, child freed after being kidnapped in Haiti last month

leisure time

leisure time

focus

In Memoriam: Notable people who died in 2023

Why failed clinical trials don’t always spell doom for a new drug

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

What does generative AI mean for health care? We asked experts

What to know about Virgin Galactic's 1st mission taking paying customers to space

As demand for Covid shots wanes, Moderna seeks its next success

Hubble vs. James Webb telescope images: See the difference

Jerome Adams on the need for new antivirals for Covid

Emergent cuts jobs, executive role in business shake

entertainment

Being 'nonadherent' patient made me a more empathetic doctor

Hubble vs. James Webb telescope images: See the difference

Prescription digital therapeutics are key to pharma’s future

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

The best solution to the drug shortages problem

knowledge

focus

hotspot

focus